IGF-1 Related Biomarker Testing: Technical Overview, Methodologies, and Clinical Applications

IGF-1 related biomarker testing is a critical laboratory tool for evaluating growth hormone activity, diagnosing growth disorders, and monitoring conditions such as acromegaly and growth hormone deficiency. Accurate measurement of IGF-1 and its associated binding proteins provides clinicians with reliable insights into the GH/IGF axis. This article covers the key analytes, sample types, analytical methods, and clinical applications of IGF-1 related indicator testing.

Technical Overview

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino-acid polypeptide hormone that mediates most of the anabolic effects of growth hormone (GH). It is produced primarily by the liver in response to GH stimulation and circulates in the bloodstream bound to specific binding proteins, with Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) being the most abundant carrier. Because GH secretion is pulsatile and varies significantly throughout the day, single GH measurements are often unreliable. In contrast, IGF-1 levels are relatively stable and reflect integrated GH activity over the preceding 24 to 48 hours, making IGF-1 the recommended first-line biomarker for assessing GH-related disorders.

IGF-1 related indicator testing encompasses a panel of analytes that together provide a comprehensive picture of the GH/IGF axis. This includes total IGF-1, free IGF-1, IGFBP-3, the acid-labile subunit (ALS), IGF-2, and the IGF-1/IGF-2 ratio. Interpretation requires age-specific and sex-specific reference ranges, as IGF-1 concentrations rise during puberty, peak in late adolescence, and decline progressively with age. Proper pre-analytical handling, including fasting sample collection and avoidance of hemolysis, is essential for accurate results.

Testing Samples

Serum

Serum is the most widely used sample type for IGF-1 testing. A venous blood sample of 2 to 5 mL is collected in a plain tube or serum separator tube, allowed to clot for 30 minutes, and centrifuged to obtain serum. Serum samples should ideally be collected in the morning after an overnight fast, since nutritional status, particularly insulin levels, can influence IGF-1 concentrations. Serum is stable at 2 to 8°C for up to 72 hours and can be stored frozen at -20°C or below for longer periods.

Plasma

Plasma collected in EDTA or heparin tubes is also acceptable for most immunoassay platforms. The anticoagulant should be compatible with the specific assay system in use. Plasma separation should occur within 2 hours of collection to minimize degradation of binding proteins. Repeated freeze-thaw cycles should be avoided, as they may alter the integrity of the IGF-1/IGFBP-3 complex and affect measured values.

Dried Blood Spots (DBS)

Dried blood spot sampling is increasingly used for population screening and pediatric applications due to its minimally invasive nature and ease of transport. A finger-prick blood sample is applied to filter paper, dried, and then eluted for analysis. DBS methods are validated primarily through LC-MS/MS and are useful for remote sampling, longitudinal monitoring, and epidemiological studies, although reference ranges may differ from those established for serum.

Cerebrospinal Fluid (CSF)

In specialized research and clinical contexts, CSF IGF-1 measurement may be performed to investigate central nervous system disorders. CSF collection requires a lumbar puncture performed under sterile conditions, and the sample must be handled with strict protocols to avoid contamination and cellular lysis.

Testing Items

A comprehensive IGF-1 related testing panel typically includes the following analytes, each offering distinct diagnostic information about the GH/IGF axis:

• Total IGF-1: The primary clinical biomarker reflecting integrated GH secretion; used for screening, diagnosis, and monitoring of acromegaly and GH deficiency.
• Free IGF-1: The biologically active, unbound fraction; measured mainly in research settings or when total IGF-1 results conflict with clinical findings.
• IGFBP-3: The principal binding protein that carries more than 75% of circulating IGF-1; useful as an adjunct marker, particularly in pediatric growth evaluation.
• Acid-Labile Subunit (ALS): A component of the ternary IGF complex; ALS deficiency causes short stature and may be evaluated when IGF-1 and IGFBP-3 are disproportionately low.
• IGF-2: Structurally similar to IGF-1 but largely GH-independent; the IGF-1/IGF-2 ratio can help identify non-islet cell tumor hypoglycemia and certain growth abnormalities.
• Growth Hormone (GH): Often measured alongside IGF-1 during suppression or stimulation testing to dynamically assess GH reserve or excess.
• IGF-1/IGFBP-3 Molar Ratio: A calculated index that may improve diagnostic sensitivity for GH excess in select populations.

Testing Methods

Several analytical platforms are available for IGF-1 related indicator testing, each with specific advantages regarding throughput, sensitivity, and standardization:

• Immunoassays (CLIA/ECLIA): Automated chemiluminescent and electrochemiluminescent immunoassays are the mainstay of routine clinical laboratories. These methods use acidic or alkaline pre-treatment to dissociate IGF-1 from binding proteins before quantification, ensuring measurement of total IGF-1. They offer rapid turnaround, high precision, and broad analytical ranges.
• Enzyme-Linked Immunosorbent Assay (ELISA): A cost-effective option suitable for smaller laboratories and research studies. ELISA provides good sensitivity but requires manual processing and careful attention to washing and incubation steps.
• Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Considered the reference methodology with superior specificity and inter-laboratory comparability. LC-MS/MS can simultaneously quantify IGF-1, IGF-2, and IGFBP-3, and it provides excellent linearity across pediatric and adult ranges. It is increasingly recommended for definitive measurement and for resolving discrepant immunoassay results.
• Radioimmunoassay (RIA): A historically important method still used in some specialized centers. While sensitive, radioisotope handling requirements have limited its routine adoption.
• Western Ligand Blotting and Proteomic Approaches: Research-grade techniques used to characterize IGFBP isoforms and post-translational modifications in investigational settings.

Quality assurance requires participation in external quality assessment schemes, use of certified reference materials such as WHO IS 02/254 for IGF-1, and application of method-specific, age-adjusted, and sex-adjusted reference intervals. Laboratories should validate assay performance characteristics including precision, accuracy, linearity, and reference ranges for their specific patient population.

Applications

IGF-1 related indicator testing supports a wide range of clinical and scientific applications:

• Diagnosis of Acromegaly and Gigantism: Elevated IGF-1 with inadequate GH suppression during oral glucose tolerance testing confirms GH excess.
• Evaluation of Growth Hormone Deficiency: Low age-adjusted IGF-1 combined with failed GH stimulation testing supports the diagnosis in children with short stature and adults with suspected hypopituitarism.
• Monitoring of Treatment Response: Serial IGF-1 measurements guide dosing of recombinant human GH therapy and assess biochemical control after surgery, pharmacological treatment, or radiotherapy for acromegaly.
• Pediatric Growth Assessment: IGF-1 and IGFBP-3 assist in distinguishing GH deficiency from constitutional delay of growth and other causes of short stature.
• Oncology and Risk Stratification: Abnormal IGF axis activity has been associated with prostate, breast, and colorectal cancers, and IGF-1 levels are used in epidemiological and therapeutic research.
• Anti-Doping Surveillance: The GH-2000 biomarker approach combining IGF-1 and P-III-NP is used by anti-doping agencies to detect GH abuse in athletes.
• Metabolic and Nutritional Assessment: IGF-1 serves as a marker of hepatic synthetic function and nutritional status, particularly in critical illness, malnutrition, and chronic liver disease.

FAQ

What is the normal reference range for IGF-1? IGF-1 reference intervals vary substantially by age, sex, and assay method. In adults, typical values range from approximately 100 to 300 ng/mL, while levels in adolescents can exceed 500 ng/mL during peak puberty. Each laboratory must establish or verify method-specific reference ranges, and results should always be interpreted using age- and sex-matched normative data.

Do I need to fast before an IGF-1 blood test? An overnight fast is recommended, ideally with morning collection. Acute nutritional intake can transiently influence IGF axis dynamics, and fasting standardization improves result comparability across serial measurements.

Can medications affect IGF-1 levels? Yes. Recombinant human GH therapy raises IGF-1, while conditions or treatments causing hypopituitarism lower it. Oral estrogens, high-dose corticosteroids, and certain hepatic enzyme inducers can also alter concentrations. Clinicians should document all medications when ordering testing.

Why is IGF-1 preferred over a single GH measurement? GH is secreted in pulses with marked diurnal variation, so random GH values are difficult to interpret. IGF-1 has a longer half-life and reflects cumulative GH secretion, providing a stable and clinically actionable indicator of GH axis status.

How are borderline or discordant results handled? When IGF-1 results are borderline or inconsistent with clinical presentation, repeat testing, confirmatory LC-MS/MS measurement, and dynamic GH testing (suppression or stimulation) are recommended before establishing or excluding a diagnosis.

Is IGF-1 testing suitable for children? Yes. IGF-1 and IGFBP-3 testing is widely used in pediatric endocrinology, with validated age-specific reference ranges from infancy through adolescence. Dried blood spot and minimal-volume methods have improved feasibility in young patients.